Related references
Note: Only part of the references are listed.
Article
Immunology
Julie Toubiana et al.
Summary: During the COVID-19 pandemic, there was an increase in multisystem inflammatory syndrome in children, including Kawasaki disease. Research showed that children with KD associated with confirmed SARS-CoV-2 infection were more likely to be of sub-Saharan African ancestry, older, exhibit more gastrointestinal and neurological symptoms, shock syndrome, and myocarditis compared to those with classic KD. These findings highlight the need for further investigation into the pathogenesis of KD-SARS-CoV-2.
JOURNAL OF CLINICAL IMMUNOLOGY
(2021)
Review
Pediatrics
Jun Yasuhara et al.
Summary: The study revealed that MIS-C results in multi-organ failure, including gastrointestinal manifestations, myocardial dysfunction, and coronary abnormalities, demonstrating distinct features from Kawasaki disease.
PEDIATRIC PULMONOLOGY
(2021)
Article
Pediatrics
Carles Bautista-Rodriguez et al.
Summary: An international survey on children diagnosed with multisystem inflammatory syndrome temporally associated with SARS-CoV-2 showed a wide clinical spectrum, including Kawasaki disease-like cases, life-threatening shock, and milder cases with mainly fever and inflammation. A shorter duration of symptoms before admission was associated with a worse outcome.
Article
Medicine, General & Internal
Guy Witberg et al.
Summary: Among 2.5 million patients who received the BNT162b2 mRNA vaccine in a large Israeli health care system, the incidence of myocarditis at 42 days was 2.13 cases per 100,000 persons, with the highest incidence (10.69 per 100,000 persons) among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
D. Mevorach et al.
Summary: The incidence of myocarditis increased after receiving the BNT162b2 vaccine in Israel, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Noa Dagan et al.
Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Public, Environmental & Occupational Health
Kate R. Woodworth et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
(2021)
Article
Pediatrics
Marco Cattalini et al.
Summary: The study indicates that SARS-CoV-2 infection can lead to two distinct inflammatory diseases in children: Kawasaki Disease and PIMS-TS. Older age and clinical peculiarities like myocarditis characterize this multi-inflammatory syndrome, with patients showing optimal response to treatments, few complications, and no deaths.
PEDIATRIC RHEUMATOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Biykem Bozkurt et al.
Summary: Myocarditis is a rare complication of COVID-19 mRNA vaccines, predominantly affecting young adult and adolescent males, with most patients showing improvement in symptoms. Possible mechanisms include molecular mimicry between viral proteins and self-antigens, dysregulated immune pathways, immune response to mRNA, and dysregulated cytokine expression.
Article
Medicine, General & Internal
Robert W. Frenck et al.
Summary: The BNT162b2 vaccine showed favorable safety profile and a greater immune response in 12-to-15-year-old recipients compared to young adults, and demonstrated high effectiveness against Covid-19.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Audrey Dionne et al.
Summary: This study reviewed comprehensive cardiac imaging results in children with myocarditis after receiving the BNT162b2 COVID-19 vaccine. Most cases of myocarditis occurred in boys after the second dose, and patients showed mild symptoms in short-term follow-up. Long-term risks of post-vaccination myocarditis remain unknown, necessitating larger studies for vaccination recommendations in this population.
Review
Medicine, General & Internal
Abhishek Matta et al.
Summary: Myocarditis as a potential complication of Pfizer-BioNTech and Moderna COVID-19 vaccines is increasing. It predominantly affects young males within a few days after the second dose. Most patients were admitted to the hospital within three days post-vaccination with symptoms of chest pain and elevated troponin, and all patients recovered and were discharged.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Infectious Diseases
Mhd Baraa Habib et al.
Summary: The widespread use of vaccines has been associated with rare but serious complications in adults, leading to global concern. This case study highlights a young male patient who developed acute myocarditis three days after receiving the second dose of the BNT162b2 vaccine.
Article
Medicine, General & Internal
Shelley Riphagen et al.
Article
Medicine, General & Internal
Edward E. Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2020)
Article
Cardiac & Cardiovascular Systems
Zubair Shah et al.
AMERICAN JOURNAL OF CARDIOLOGY
(2019)
